Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk
Open Access
- 27 December 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (3) , 5361-5370
Abstract
Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-B and BtkKeywords
This publication has 33 references indexed in Scilit:
- Differential regulation of miR-21 and miR-146a by Epstein–Barr virus-encoded EBNA2Leukemia, 2012
- Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growthProceedings of the National Academy of Sciences, 2011
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaBlood, 2011
- Comprehensive assessment of chemokine expression profiles by flow cytometryJournal of Clinical Investigation, 2010
- Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac riskAnnals of Oncology, 2009
- Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1FEBS Letters, 2007
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesNew England Journal of Medicine, 2004
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Tumorigenicity of EBNA2-transfected cellsFEBS Letters, 1995
- Masking of the CBF1/RBPJ κ Transcriptional Repression Domain by Epstein-Barr Virus EBNA2Science, 1995